Ibogaine: A potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors

Molecular Pharmacology

Volumn 51, Issue 1, 1997, Pages 1-5

  Badio, Barbara ^a   Padgett, William L ^a   Daly, John W ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DESMETHYLIBOGAINE; 2 TERT BUTYL 2 DESMETHYLIBOGAINE; EPIBATIDINE; IBOGAINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE NA 22; UNCLASSIFIED DRUG;

ADDICTION; ANIMAL CELL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031024617     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.1.1     Document Type: Article

References (29)

1. Popik, P., R. T. Layer, and P. Skolnick. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47:235-253 (1995).
2. Deecher, D. C., M. Teitler, D. M. Soderlund, W. G. Bornmann, M. E. Kuehne, and S. D. Glick. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 571:242-247 (1992).
3. Sweetnam, P. M., J. Lancaster, A. Snowman, J. L. Collins, S. Perschke, C. Bauer, and J. Ferkany. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology 118:369-376 (1995).
4. 2 receptors. Life Sci. 57:57-62 (1995).
5. Codd, E. E. High affinity ibogaine binding to a mu opioid agonist site. Life Sci. 57:315-320 (1995).
6. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology 114:672-674 (1994).
7. Popik, P., R. T. Layer, L. Fossom, M. Benvensite, B. Getter-Douglass, J. M. Witkin, and P. Skolnick. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J. Pharmacol. Exp. Ther. 275:753-760 (1995).
8. Frances, B., R. Gout, J. Cros, and J. M. Zajac. Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice. Fundam. Clin. Pharmacol. 6:327-332 (1992).
9. Layer, R. T., P. Skolnick, C. M. Bertha, U. K. Bandarage, M. E. Kuehne, and P. Popik. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. Eur. J. Pharmacol. 309:159-165 (1996).
10. Pearl, S. M., D. W. Johnson, and S. D. Glick. Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation. Psychopharmacology 121:470-475 (1995).
11. Sershen, H., A. Hashim, L. Harsing, and A. Lajtha. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sci. 50:1079-1086 (1992).
12. Pearl, S. M., K. Herrick-Davis, M. Teitler, and S. D. Glick. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine. Brain Res. 675:342-344 (1995).
13. 2 receptor-selective ligands with moderate affinity. Eur. J. Pharmacol. 279:R1-R3 (1995).
14. Popik, P., and P. Skolnick. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53:791-797 (1996).
15. Glick, S. D., K. Rossman, S. Steindorf, I. M. Maisonneuve, and J. N. Carlson. Effects and after effects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:341-345 (1991).
16. Glick, S. D., S. M. Pearl, J. Cai, and I. M. Maisonneuve. Ibogaine-like effects of noribogaine in rats. Brain Res. 713:294-297 (1996).
17. Badio, B., and J. W. Daly. Epibatidine, a potent analgetic and nicotimc agonist. Mol. Pharmacol. 45:563-569, 1994.
18. Clarke, P. B. S., and H. El-Bizri. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro. Br. J. Pharmacol. 111: 406-413 (1994).
19. Clarke, P. B. S., I. Chaudieu, H. El-Bizri, P. Boksa, M. Quik, B. A. Esplin, and R. Capek. The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion. Br. J. Pharmacol. 111:397-405 (1994).
20. Badio, B., D. Shi, H. M. Garraffo, and J. W. Daly. Antinociceptive effects of the alkaloid epibatidine: further studies on involvement of nicotinic receptors. Drug Dev. Res. 36:46-59 (1995).
21. Tsai, M.-C., N. A. Mansour, A. T. Eldefrawi, M. E. Eldefrawi, and E. X. Albuquerque. Mechanism of action of amantadine on neuromuscular transmission. Mol. Pharmacol. 14:787-803 (1978).
22. Damaj, M. I., K. R. Creasy, A. D. Grove, J. A. Rosecrans, and B. R. Martin. Pharmacological effects of epibatidine optical enantiomers. Brain Res. 664:34-40 (1994).
23. 2 receptor. J. Pharmacol. Exp. Ther. 276:289-297 (1996).
24. Benwell, M. E. M., P. E. Holtom, R. J. Moran, and D. J. K. Balfour. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br. J. Pharmacol. 117:743-749 (1996).
25. 3H]-dopamine release. Br. J. Pharmacol. 117:595-606 (1996).
26. Sershen, H., A. Hashim, and A. Lajtha. The effect of ibogaine on sigma- and NMDA-receptor-mediated release of dopamine. Brain Res. Bull. 40: 63-67 (1996).
27. Bowen, W. D., B. J. Vilner, U. K. Bandarage, and M. E. Kuehne. Ibogaine and ibogaine modulate intracellular calcium levels via interaction with sigma-2 receptors. Soc. Neurosci. Abstr. 26:2006 (1996).
28. Mulder, A. H., G. Wardeh, F. Hogenboom, and A. L. Frankhuyzen. κ-δ-Opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature (Lond.) 308:278-280 (1984).
29. Sershen, H., A. Hashim, and A. Lajtha. The effect of ibogaine on kappa-opioid- and 5-HT3-induced changes in stimulation-evoked dopamine release in vitro from striatum of C57BL/6By mice. Brain Res. Bull. 36:587-591 (1995).